Fabtech Technologies Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/v27tel3u56plmpozeurnkc3g.pdf

Key Takeaways


Execution & the H2 Bet

Aman Anavkar: "Our guidance remains the same. We are very confident of the coming two quarters and our performance will speak."

Margin Mechanics

Aman Anavkar: "Right now the raw material costs are extremely high and we're closing orders based on these current prices. So later on when the war actualizes, freight goes down, RMC goes down, what kind of impact do you think will be on the margins for us?"

Geopolitics: Cost, Collections & Continuity

Aman Anavkar: "There has definitely been an impact on the raw materials and the freight and the security measures that we talked about so that our people could perform and execute the projects smoothly. But each and every situation we have dealt with and there is a deliberate action that we are taking to ensure that our investors are secure, our company is secure and our people most important on site are secure."

Diversification: Geographies, Sectors & the Moat

Aman Anavkar: "Every project we deliver becomes that proof of reference. More references lead us to enter more geographies. ... Large projects build deeper customer trust and that trust brings the next round of projects. And this is the loop, this is the cycle, each time from a higher base."

M&A and Strategic Initiatives

Ashwani Singh: "Every JV will be announced with a clear vision for the next three years at a specific growth rate."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenue growth25% to 30% year-on-year growthFY27
Adjusted PAT margin exit8% to 9%End of FY27
European acquisition closeDue diligence positive; close expectedWithin six months or Q1 FY28
Saudi JV disclosureFormal announcement with three-year growth visionIn another quarter
Revenue recognition methodMove to project-completion basisTarget FY28
IPO proceeds utilizationUtilization to be completedEnd of FY27
Operating cash flowReturn to positiveBy March (FY27 year-end)
Order book replenishmentINR 800–850 crore of new orders expected from Middle East and AfricaNext 12 months (conversion from hot pipeline)
Medium-term growth run rate25% to 30% annual growthNext 3 to 5 years
ROE ambitionGrow to 20–30%+; "maybe we will be very close to 30% or more than 30%"Two year, three year down the line

Key Metrics

MetricQ2 FY27
Revenue₹92.09 cr, +22.8% QoQ; down 24% YoY
Total income₹97.54 cr, +24.8% QoQ
EBITDA₹15.57 cr, +110% QoQ
EBITDA margin16%, expanded 647 bps QoQ
Reported PAT₹15.02 cr, vs ₹4.21 cr in Q1 FY27
Exceptional item (net of tax)₹6.59 cr
Adjusted PAT₹8.45 cr, vs ₹4.21 cr in Q1 FY27
Adjusted PAT margin9.2%, expanded 354 bps QoQ
Order bookOver ₹900 cr, approximately 2.2x last year's revenue
Additional pipeline beyond order book₹800 cr to ₹850 cr of added revenue expected over the next one year
Saudi Arabia revenue₹46.2 cr, +18.5% YoY
Africa revenue (Morocco, Kenya, Algeria)~₹47 cr combined
India revenue share16% of total revenue
Group receivables (gross)₹235 cr at September end; net ₹226 cr after ECL provisioning
Overdue receivables₹81 cr, of which ₹25 cr retention and ~₹50 cr being collected in coming months
Operating cash flow (H1 FY27)~₹41 cr
Cash and bank balanceMore than ₹200 cr
Current ROE~9%
FY27 adjusted PAT margin target8% to 9% at year-end
Medium-term revenue growth target25% to 30% YoY
Hot pipeline₹3,600 cr to ₹4,000 cr
Expected order conversion in next 12 months₹800 cr to ₹850 cr
In-house manufactured share of design-and-build project30%
Global turnkey pharma and biotech market$180 bn, growing at ~8% CAGR
Serviceable market (GCC, Africa, MENA)$28 bn to $30 bn
Saudi Arabia pharma manufacturing investment (Vision 2030)Over $15 bn
Africa medicine production investment (until 2040)Over $60 bn
Fabtech scope of typical project spend~50%
Data centre scope of work for Fabtech~30% of total project value
Margin expansion target from strategic initiatives2% to 3% addition to PAT from each strategy over next 2–3 years
PEB share of project pipeline~20%
Land acquired at Khalapur₹18.6 cr
FY25 sales commission to G7 Universal LLC (related party)₹3.6 cr